Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Beta-2 microglobulin: a prognostic factor in diffuse aggressive non-Hodgkin's lymphomas

P W Johnson1, J Whelan, S Longhurst

  • 1I.C.R.F. Department of Medical Oncology, St Bartholomew's Hospital, London, UK.

British Journal of Cancer
|April 1, 1993
PubMed
Summary

Elevated beta-2 microglobulin indicates advanced lymphoma and predicts poor treatment response. Normal levels correlate with higher remission rates, longer remission duration, and improved survival in high-grade lymphoma patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expanding the phenotypic spectrum of DNAJC21-associated bone marrow failure syndrome: A single-centre experience.

British journal of haematology·2026
Same author

Purkinje cell collaterals preferentially target a subtype of molecular layer interneuron.

bioRxiv : the preprint server for biology·2025
Same author

Search for the Anomalous Events Detected by ANITA Using the Pierre Auger Observatory.

Physical review letters·2025
Same author

Inference of the Mass Composition of Cosmic Rays with Energies from 10^{18.5} to 10^{20}  eV Using the Pierre Auger Observatory and Deep Learning.

Physical review letters·2025
Same author

Search for Leptonic Decays of Dark Photons at NA62.

Physical review letters·2024
Same author

Demonstrating Agreement between Radio and Fluorescence Measurements of the Depth of Maximum of Extensive Air Showers at the Pierre Auger Observatory.

Physical review letters·2024

Area of Science:

  • Oncology
  • Hematology
  • Biochemistry

Background:

  • High-grade lymphoma is a significant hematologic malignancy.
  • Accurate prognostic markers are crucial for treatment stratification.
  • Beta-2 microglobulin (B2M) is a protein found on cell surfaces.

Purpose of the Study:

  • To investigate the prognostic value of serum beta-2 microglobulin (B2M) levels in patients with high-grade lymphoma.
  • To determine the association of B2M with disease stage, response to chemotherapy, and survival outcomes.

Main Methods:

  • Serum samples from 262 high-grade lymphoma patients were analyzed for beta-2 microglobulin (B2M) levels.
  • Patients received combination chemotherapy over a 15-year period.
  • Statistical analyses, including multivariate analysis, were performed to assess prognostic factors.

Related Experiment Videos

Main Results:

  • Elevated B2M levels were significantly associated with advanced Ann Arbor stage (III/IV) and hepatic infiltration.
  • Patients with normal B2M had a 70% remission rate versus 37% with elevated levels (P < 0.001).
  • Normal B2M predicted significantly longer remission duration (plateau at 70% vs. 19 months) and improved overall survival (median 9 years vs. 1 year).

Conclusions:

  • Serum beta-2 microglobulin (B2M) is a potent independent prognostic marker in high-grade lymphoma.
  • Elevated B2M levels are linked to adverse prognostic factors and poorer outcomes.
  • B2M measurement can aid in predicting treatment response, remission duration, and survival.